Teva gets FDA approval for cancer drug

[December 09, 2015]    (Reuters) - Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine.

The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.

Teva, which has licensed the drug from Eagle Pharmaceuticals Inc, is responsible for all U.S. commercial activities for Bendeka.

(Reporting by Shailesh Kuber; Editing by Saumyadeb Chakrabarty)

[© 2015 Thomson Reuters. All rights reserved.]

Copyright 2015 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.